Format

Send to

Choose Destination
Z Gastroenterol. 2017 Apr;55(4):369-374. doi: 10.1055/s-0042-121520. Epub 2017 Jan 5.

[Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists].

[Article in German]

Author information

1
Gastroenterologische Gemeinschaftspraxis Minden, Minden.
2
Medizinische Klinik I, Agaplesion Markus Krankenhaus, Frankfurt/Main.
3
Klinik Innere Medizin I, Universitätsklinik Schleswig-Holstein, Campus Kiel, Kiel.

Abstract

The European Medicines Agency (EMA) recently approved the first anti-TNF-alpha biosimilar for infliximab (CT-P13) (trade names: Inflectra® and Remsima®) in Germany. Over the past year, German gastroenterologists gained experience treating IBD-patients with infliximab biosimilars (IFX-biosimilars). To evaluate their experiences and opinions on biosimilars, we conducted a nationwide online survey among German gastroenterologists. Our results are based on the assessment of 449 questionnaires. Although 61 % of the participants had already prescribed IFX-biosimilars, about two thirds of these participating gastroenterologists with IFX-biosimilar prescription stated their experience as based on fewer than 10 IBD-patients treated with IFX-biosimilars. Only 15 % considered themselves to be very experienced with biosimilars. The lower price in comparison to the originator is seen as the most important advantage of biosimilars (71 %). More than two thirds of the survey participants requested specific gastroenterological trials and registries to increase the data available on biosimilars in IBD-patients (68 %).

PMID:
28056484
DOI:
10.1055/s-0042-121520

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center